Cellectis: Monthly Information on Share Capital and Company Voting Rights
December 06 2018 - 4:10PM
Business Wire
(Article 223-16 of General Regulation of the
French financial markets authority)
Regulatory News:
Cellectis (Paris:ALCLS):
Listing market: Euronext Growth
ISIN code: FR0010425595
Date
Total number of sharesin the
capital
Total number of
votingrights
11/30/2018 42,430,026 47,447,187
About CellectisCellectis is a clinical-stage
biopharmaceutical company focused on developing a new generation of
cancer immunotherapies based on gene-edited T-cells (UCART). By
capitalizing on its 18 years of expertise in gene editing – built
on its flagship TALEN® technology and pioneering electroporation
system PulseAgile – Cellectis uses the power of the immune system
to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.Cellectis is listed
on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS). To find out more about us, visit our website:
www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181206005433/en/
CellectisMedia:Jennifer Moore917-580-1088VP of
Communicationsmedia@cellectis.com
Caitlin Kasunich212-896-1241KCSA Strategic
Communicationsckasunich@kcsa.com
IR:Simon Harnest646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
From Apr 2023 to Apr 2024
